logo
EVs widen life-cycle emissions gap over combustion cars, new study finds

EVs widen life-cycle emissions gap over combustion cars, new study finds

Yahoo10-07-2025
An increase in sustainable energy in Europe is making battery-electric vehicles substantially cleaner over their life cycles compared with combustion-engine cars, according to a new report from the International Council on Clean Transportation.
New BEVs will produce 73 percent fewer CO2 emissions than gasoline-powered cars, the ICCT said in a report July 9. That figure is 24 percent better than a 2021 estimate from the group.
In addition to taking advantage of renewable energy for charging and production, BEVs have also become more efficient, Marta Negri, a researcher at the ICCT, said.
'Battery electric cars in Europe are getting cleaner faster than we expected and outperform all other technologies, including hybrids and plug-in hybrids,' Negri said in a release.
In contrast, combustion-engine-based cars, including full hybrids and plug-in hybrids, have been getting only marginally cleaner in recent years, the group said. Hybrids have life-cycle emissions that are 20 percent lower than gasoline models, while PHEV emissions are 30 percent lower.
'When running on the EU average fuel and electricity mix, only BEVs offer a large-scale reduction in life-cycle GHG emissions,' the report said, referring to greenhouse-gas emissions.
Sign up for the Automotive News Europe Focus on Electrification newsletter, a weekly wrap-up of the latest electric vehicle news, including interviews and global EV sales data.
The ICCT study considered sales-weighted characteristics of compact cars sold in the EU in 2023 and assumes a life cycle of 20 years.
Renewable energy such as solar and wind is expected to make up 56 percent of Europe's mix, an 18-percentage-point gain from 2020, and could be 86 percent by 2045, the ICCT said, citing figures from the European Union.
Life-cycle assessment is a way to measure the carbon footprint of a car, from raw materials extraction, component manufacturing, production, energy consumption (including how the energy is produced) and end of life disposal or recycling.
Proponents say it is more accurate than current emissions standards, which focus on tailpipe emissions, while critics say life-cycle data can be selectively manipulated.
Earlier life-cycle assessment studies 'have repeatedly demonstrated that battery-electric vehicles eliminate tailpipe GHG emissions and represent the most promising pathway for rapidly reducing life-cycle emissions,' the ICCT said, while acknowledging that 'given varying scopes and inconsistent methodological choices, individual LCA studies can yield widely differing and sometimes contradictory results.'
Critics of EVs, for example, say that emissions from battery production are often so high that they cannot be offset by zero tailpipe emissions. The ICCT, in its report, acknowledged this claim but said that this 'emission debt' can be offset after 17,000 km of driving.
The European Commission and the United Nations Economic Commission for Europe (UNECE) are currently working on harmonizing life-cycle assessment measurements. Automakers will be able to voluntarily report their cars' life-cycle emissions starting next year using the commission's methodology.
A gasoline car has life-cycle emissions of 235 grams of CO2 per km based on the average European power grid (assuming current mix of renewable and nonrenewable energy), while an EV's emissions are 63 g/km, the ICCT said (see chart, above). Plug-in hybrid emissions are 163 g/km, while full hybrids are 188 g/km.
The report argues that electric cars' life-cycle emissions are often overstated because they are based on a static electricity grid mix, rather than assuming that the percentage of renewable energy will continue to increase.
In addition, a shorter life-cycle assumption (less than 20 years) also tends to disadvantage EVs, as does a discrepancy between as-tested and real-world usage — for example, in-car monitoring has found that PHEV emissions are up to 3.5 times higher than tested, because owners do not regularly charge the batteries.
If these factors are not considered, the ICCT said, life-cycle emissions of BEVs can be up to 64 percent higher. 'Under such conditions, BEVs appear to have emissions levels comparable to PHEVs,' the report said.
Other findings of the study:
Production and recycling emissions were roughly equivalent across fuel types, ranging from 6.5 metric tons for BEVs to 7.9 tons for PHEVs (because of their complexity).
Battery production had emissions of 3.9 tons of CO2 for BEVs and 1.0 ton for PHEVs.
Maintenance: BEVs had emissions of 4 g/km (largely because they need fewer consumable items such as spark plugs or belts), while diesel maintenance was 7 g/km (due in part to the need for urea in exhaust treatment) and gasoline cars had maintenance emissions of 6 g/km.
Fuel-cell EVs have the potential to reduce life-cycle greenhouse gas emissions by 79 percent, but only if they use hydrogen that is processed using renewable electricity.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

Yahoo

time20 minutes ago

  • Yahoo

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

– Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZA – – European Commission decision expected by Q4 2025 – CARLSBAD, Calif., July 25, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The positive opinion is now referred to the European Commission (EC) for an approval decision, which is expected by Q4 2025. "Building on the strong early launch of TRYNGOLZA in the U.S., the positive CHMP opinion advances our commitment to expand access to TRYNGOLZA globally," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "TRYNGOLZA has demonstrated significant reductions in triglycerides and substantial reductions in acute pancreatitis events with favorable safety and tolerability. With this robust clinical profile, combined with Sobi's deep commercial market expertise in FCS, TRYNGOLZA has the potential to make a meaningful difference for people living with FCS in the EU." The CHMP opinion is based on positive data from the Phase 3 Balance study, in which TRYNGOLZA demonstrated a statistically significant reduction in triglyceride levels at six months that was sustained through 12 months. Additionally, TRYNGOLZA demonstrated a substantial and clinically meaningful reduction in acute pancreatitis events over 12 months. TRYNGOLZA showed a favorable safety and tolerability profile. Study results were published in The New England Journal of Medicine (NEJM). FCS is a rare and genetic form of severe hypertriglyceridemia (sHTG) that prevents the body from breaking down fats and severely impairs the ability to remove triglycerides from the bloodstream. People with FCS often have triglyceride levels of more than 880 mg/dL (10 mmol/L), compared to normal levels of <150 mg/dL (1.7 mmol/L), and are at high risk of developing acute pancreatitis, which can be life-threatening. In the EU, FCS is estimated to impact up to 13 people per million. Sobi has exclusive rights to commercialize TRYNGOLZA in countries outside the U.S., Canada and China. As Ionis' European commercial partner for Waylivra (volanesorsen), the only medicine currently approved for FCS in the EU, Sobi will leverage existing market expertise and distribution channels to enable an effective TRYNGOLZA launch in FCS, if approved. "The approval recommendation brings us one step closer toward delivering TRYNGOLZA to people living with FCS in the EU and is a testament to our long-standing support for the FCS community," said Lydia Abad-Franch, M.D., MBA, head of research, development and medical affairs and chief medical officer, Sobi. "Patients with FCS suffer from complications such as acute pancreatitis. These are very severe events, often requiring intensive care and sometimes causing multiorgan failure as well as increasing morbidity and mortality. We believe TRYNGOLZA has the potential to be an important treatment for people living with this rare and serious disease, and we look forward to the final decision from the EC later this year." TRYNGOLZA was approved in the United States in December 2024 and granted orphan designation in the EU. Olezarsen is also being evaluated for sHTG, a serious condition defined by dangerously high triglycerides (≥500 mg/dL), and data from the Phase 3 CORE and CORE2 studies are expected in Q3 2025. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. People living with FCS are at high risk of acute pancreatitis in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About TRYNGOLZA® (olezarsen) TRYNGOLZA® is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. TRYNGOLZA® (olezarsen) is approved in the United States as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). For more information about TRYNGOLZA, visit TRYNGOLZA is not yet approved for any indication in Europe. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of our commercial medicines, olezarsen, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals® and TRYNGOLZA® are trademarks of Ionis Pharmaceuticals, Inc. View source version on Contacts Ionis Investor Contact: D. Wade Walke, 760-603-2331Ionis Media Contact: Hayley Soffermedia@ 760-603-4679 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Digital rights groups file antitrust complaint against Alphabet
Digital rights groups file antitrust complaint against Alphabet

Yahoo

time20 minutes ago

  • Yahoo

Digital rights groups file antitrust complaint against Alphabet

Six digital and human rights organisations have filed an antitrust complaint in the European Union (EU) against Alphabet, the parent company of Google. According to a Reuters report, the complaint urges EU regulators to investigate whether Alphabet complies with the Digital Markets Act (DMA), particularly regarding the ease of uninstalling software applications. The DMA, which came into effect two years ago, establishes a set of rules for major technology companies, such as Alphabet, to limit their market dominance and expand consumer options. The organisations who filed the complaint include ARTICLE 19, European Digital Rights (EDRi), Free Software Foundation Europe (FSFE), Gesellschaft fur Freiheitsrechte (GFF), Homo Digitalis, and They alleged that Alphabet has not adhered to the DMA's stipulations. The groups claim that Alphabet has structured its Android operating system in a way that obscures the option for users to disable its pre-installed applications. 'Alphabet has designed its Core Platform Service Android in a way to hide from end users the possibility to disable its own pre-installed gatekeeper apps. 'What is more, Alphabet goes to great length to scare away end users who have found that possibility against all odds of actually disabling Google's pre-installed apps,' the news agency quoted the organisations as saying in the complaint. They urged the European Commission to conduct an investigation into these practices. However, Alphabet has denied the allegations. A Google spokesperson told Reuters: 'It is easy to uninstall apps on Android devices, so this complaint does not represent a genuine user concern.' The European Commission has acknowledged receipt of the complaint and is currently evaluating it through its standard assessment procedures. Google is also reportedly dealing with another antitrust complaint in the EU filed by a group of independent publishers over its AI Overviews feature. The complaint accuses Google of exploiting its market dominance in the online search sector. "Digital rights groups file antitrust complaint against Alphabet" was originally created and published by Verdict, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store